共 50 条
- [1] Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)Simmons, DanielDerSarkissian, MaralShenolikar, RahulWang, Min-JungLax, AngelaMuthukumar, ArunaLaliberte, FrancoisDuh, Mei Sheng
- [2] Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line settingCANCER MEDICINE, 2023, 12 (12): : 13415 - 13425Apple, JonShenolikar, RahulDe Silva, KevinSun, PingSpira, Alexander
- [3] First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is...CLINICAL ONCOLOGY, 2017, 29 (01) : E1 - E4Juan, O.Yousaf, N.Popat, S.
- [4] Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancerINTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 34 (03) : 416 - 423Moriya, TetsujiHamaji, MasatsuguYoshizawa, AkihikoMiyata, RyoNoguchi, MisaTamari, ShigeyukiChiba, NaohisaMiyamoto, HideakiToyazaki, ToshiyaTanaka, SatonaYamada, YoshitoYutaka, YojiroNakajima, DaisukeOhsumi, AkihiroMenju, ToshiDate, Hiroshi
- [5] THE REAL-WORLD EFFICACY OF FIRST-LINE TYROSINE KINASE INHIBITORS IN ASIAN PATIENTS WITH EGFR MUTATION NON-SMALL CELL LUNG CANCERRESPIROLOGY, 2018, 23 : 21 - 22Su, Vincent Yi-FongYang, Kuang-YaoChen, Yuh-Min
- [6] Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutationTHORACIC CANCER, 2016, 7 (05) : 614 - 618Huang, AimiLi, RongZhao, JikaiWang, XiaofeiJin, BoNiu, YanjieZhang, JieJiang, LiyanHan, Baohui
- [7] Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world settingJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (11) : 9243 - 9252Kraskowski, OliverStratmann, Jan A.Wiesweg, MarcelEberhardt, WilfriedMetzenmacher, MartinSchmid, Kurt W.Herold, ThomasSchildhaus, Hans-UlrichDarwiche, KaidAigner, ClemensStuschke, MartinLaue, KatharinaZaun, GregorKasper, StefanHense, JorgSebastian, MartinSchuler, MartinPogorzelski, Michael
- [8] Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world settingJournal of Cancer Research and Clinical Oncology, 2023, 149 : 9243 - 9252Oliver KraskowskiJan A. StratmannMarcel WieswegWilfried EberhardtMartin MetzenmacherKurt W. SchmidThomas HeroldHans-Ulrich SchildhausKaid DarwicheClemens AignerMartin StuschkeKatharina LaueGregor ZaunStefan KasperJörg HenseMartin SebastianMartin SchulerMichael Pogorzelski
- [9] Real-world outcomes of fi rst-line platinum doublet chemotherapy plus Tyrosine Kinase Inhibitors (TKI) in advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)ANNALS OF ONCOLOGY, 2024, 35 : S1656 - S1657Low, Y. F.Lai, G.Seet, A.Tan, W. C.Tan, A. C.Chan, J.Teh, Y. L.Tan, W. L.Jain, A.Ng, Q. S.Ang, M-KKanesvaran, R.Lim, D. W. T.Tan, D. S. W.Saw, P. L. S.
- [10] Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort studyTRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2229 - +Zhang, DongmingLiu, XiaoyanShen, FangfangZhao, DahaiShi, YuequanZhang, HaoranLiu, JiaGao, XiaoxingChen, MinjiangZhao, JingZhong, WeiGao, JunzhenHe, MinLiu, YonggangYang, XiaolingQin, JianwenTang, YulingMu, XinlinGu, YangchunZhang, ShucaiChen, XueqinPang, LiMeng, QingweiGuo, YeZhang, YuhuiLi, WeiXing, PuyuanCheng, YuanXin, TaoLi, QingxiaLi, YuChen, JunGao, FengJin, BoRossi, AntonioAdachi, HiroyukiGuerrera, FrancescoHusain, HatimXu, YanWang, Mengzhao